Antibe Therapeutics Inc (ATBPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Operating Expenses | 3,375 | 4,061 | 4,671 | 2,582 | 3,437 |
| Operating Income | -3,375 | -4,061 | -4,671 | -2,582 | -3,437 |
| Interest Expense | 0 | -330 | 0 | 0 | 2 |
| Other Income | 281 | 0 | 368 | 262 | 339 |
| Pre-tax Income | -3,094 | -3,731 | -4,304 | -2,320 | -3,100 |
| Net Income Continuous | -3,094 | -3,731 | -4,304 | -2,320 | -3,100 |
| Net Income Discontinuous | N/A | N/A | N/A | -242 | -82 |
| Net Income | $-3,094 | $-3,731 | $-4,304 | $-2,562 | $-3,182 |
| EPS Basic Total Ops | -0.06 | -0.07 | -0.08 | -0.05 | -0.06 |
| EPS Basic Continuous Ops | -0.06 | -0.07 | -0.08 | -0.04 | -0.06 |
| EPS Diluted Total Ops | -0.06 | -0.07 | -0.08 | -0.05 | -0.06 |
| EPS Diluted Continuous Ops | -0.06 | -0.07 | -0.08 | -0.04 | -0.06 |
| EPS Diluted Before Non-Recurring Items | -0.06 | -0.07 | -0.08 | -0.04 | -0.06 |
| EBITDA(a) | $-3,375 | $-4,061 | $-4,671 | $-2,582 | $-3,437 |